MX2016000751A - Una nueva forma cristalina de un derivado de bencimidazol y un metodo de preparacion de los mismos. - Google Patents

Una nueva forma cristalina de un derivado de bencimidazol y un metodo de preparacion de los mismos.

Info

Publication number
MX2016000751A
MX2016000751A MX2016000751A MX2016000751A MX2016000751A MX 2016000751 A MX2016000751 A MX 2016000751A MX 2016000751 A MX2016000751 A MX 2016000751A MX 2016000751 A MX2016000751 A MX 2016000751A MX 2016000751 A MX2016000751 A MX 2016000751A
Authority
MX
Mexico
Prior art keywords
crystal form
derivative
bencimidazol
preparation
same
Prior art date
Application number
MX2016000751A
Other languages
English (en)
Other versions
MX359916B (es
Inventor
Eun Sun Kim
Ju Kim Young
Yun LEE Ji
Woo LEE Hyuk
Hong Kweon Jae
Ah LEE Sung
Do Choi Kwang
Hyun Ko Dong
Pyeong HEO Seung
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56417901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016000751(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of MX2016000751A publication Critical patent/MX2016000751A/es
Publication of MX359916B publication Critical patent/MX359916B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a una nueva forma cristalina de un derivado de bencimidazol y un procedimiento de preparación de estos. La nueva forma cristalina de acuerdo con la presente invención apenas cambia de forma química y/o física en un estado de foto-estrés de largo plazo, tiene higroscopicidad baja y tiene una capacidad inductora de electricidad estática extremadamente baja, de este modo es ventajosa para la formulación, y debido a la excelente estabilidad de la forma de cristal misma, es muy útil para el almacenamiento a largo plazo del compuesto.
MX2016000751A 2015-01-20 2016-01-19 Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos. MX359916B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150009326A KR101684053B1 (ko) 2015-01-20 2015-01-20 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법

Publications (2)

Publication Number Publication Date
MX2016000751A true MX2016000751A (es) 2016-08-11
MX359916B MX359916B (es) 2018-10-15

Family

ID=56417901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000751A MX359916B (es) 2015-01-20 2016-01-19 Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos.

Country Status (33)

Country Link
US (1) US9908870B2 (es)
EP (1) EP3248967B1 (es)
JP (2) JP6535748B2 (es)
KR (1) KR101684053B1 (es)
CN (2) CN111187259B (es)
AR (1) AR103444A1 (es)
BR (1) BR102016001167B1 (es)
CL (1) CL2017001377A1 (es)
CO (1) CO2017005396A2 (es)
CY (1) CY1123423T1 (es)
DK (1) DK3248967T3 (es)
EA (1) EA030919B1 (es)
EC (1) ECSP17035416A (es)
ES (1) ES2816646T3 (es)
GE (2) GEAP201914554A (es)
HR (1) HRP20201275T1 (es)
HU (1) HUE050979T2 (es)
IL (1) IL253186B (es)
JO (1) JO3592B1 (es)
LT (1) LT3248967T (es)
MX (1) MX359916B (es)
MY (1) MY186830A (es)
PH (2) PH12016000029A1 (es)
PL (1) PL3248967T3 (es)
PT (1) PT3248967T (es)
RS (1) RS60758B1 (es)
SA (1) SA517381904B1 (es)
SG (1) SG10201509488YA (es)
SI (1) SI3248967T1 (es)
SM (1) SMT202000688T1 (es)
TW (1) TWI589575B (es)
UY (1) UY36521A (es)
WO (1) WO2016117814A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101829706B1 (ko) 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
KR20230114163A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법
KR20230114164A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 벤즈이미다졸 유도체의 공동 무정형 고형체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
KR20240028127A (ko) 2022-08-24 2024-03-05 위더스제약주식회사 테고프라잔 고체분산체 조성물
WO2024045255A1 (zh) * 2022-08-30 2024-03-07 上海皓元医药股份有限公司 一种特戈拉赞晶型b及其制备方法
KR102939994B1 (ko) 2023-01-05 2026-03-19 위더스제약주식회사 무정형 테고프라잔 고체분산체
KR20240120271A (ko) 2023-01-31 2024-08-07 주식회사 엔비피헬스케어 신규한 테고프라잔 말론산 공무정형
KR20250149709A (ko) * 2023-02-18 2025-10-16 리 파르마 리미티드 포타슘-경쟁적 위산분비 차단제의 안정한 비정질 형태 및 이의 제조 방법
KR20240131641A (ko) 2023-02-24 2024-09-02 엠에프씨 주식회사 신규 테고프라잔의 염 결정형 및 이의 용매화물 결정형, 및 이들의 제조방법
KR102715562B1 (ko) 2023-03-16 2024-10-11 (주) 에프엔지리서치 테고프라잔의 신규 염 및 이의 제조 방법
CN116178352A (zh) * 2023-03-16 2023-05-30 宙晟智维生命科学(上海)有限公司 一种氮稠杂环化合物的晶型及其制备方法
WO2024210689A1 (ko) 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
KR20240160980A (ko) 2023-05-03 2024-11-12 구주제약주식회사 신규한 테고프라잔 공무정형
CN116621821A (zh) * 2023-05-29 2023-08-22 宙晟智维生命科学(上海)有限公司 一种无定形的苯并咪唑基化合物及固体分散体
KR20240171566A (ko) 2023-05-31 2024-12-09 주식회사 셀트리온제약 테고프라잔의 신규한 공동무정형 및 이를 포함하는 약학 조성물
KR20240171624A (ko) 2023-05-31 2024-12-09 권대길 치환된 벤즈이미다졸의 결정형 및 이의 제조방법
WO2024253265A1 (ko) * 2023-06-09 2024-12-12 이니스트에스티 주식회사 크로메인 치환 벤즈이미다졸 유도체 및 염화아연을 포함하는 공결정 고체 및 그 제조방법
CN116715660A (zh) * 2023-06-14 2023-09-08 上海柏狮生物科技有限公司 一种特格拉赞的无定型物及其制备方法
KR102866076B1 (ko) * 2023-07-05 2025-09-29 주식회사 다산제약 고순도의 무정형 테고프라잔 제조방법
KR20250041270A (ko) 2023-09-18 2025-03-25 (주)국전약품 벤즈이미다졸 유도체의 공결정화물, 및 이를 포함하는 약제학적 조성물
KR20250066641A (ko) 2023-11-07 2025-05-14 엠에프씨 주식회사 테고프라잔 말리에이트염 1수화물 결정형 및 이의 제조방법
CN121925417A (zh) * 2023-12-08 2026-04-24 钟根堂股份有限公司 新颖的替戈拉生磺酸盐的晶型及包括其的药物组合物
KR20250118583A (ko) 2024-01-30 2025-08-06 진양제약주식회사 테고프라잔을 포함하는 제약 조성물
KR20250140387A (ko) 2024-03-18 2025-09-25 최광진 벤즈이미다졸 유도체 약물의 신규한 공결정 소재 및 그의 제조방법
CN120923480A (zh) * 2024-05-10 2025-11-11 上海新礼泰药业有限公司 替戈拉生富马酸单乙酯、其制备方法、药物组合物及应用
KR20260012908A (ko) 2024-07-19 2026-01-27 주식회사 경보제약 신규한 테고프라잔 산 부가염 및 이의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043063A1 (es) * 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
CA2608582A1 (en) * 2005-06-14 2006-12-21 Pfizer Inc. Chromane substituted benzimidazole derivatives as acid pump antagonists
BR122020004679B1 (pt) * 2005-12-19 2021-09-21 Raqualia Pharma Inc Composição farmacêutica
RU2519717C2 (ru) * 2008-07-03 2014-06-20 Рациофарм Гмбх Кристаллические соли ситаглиптина
US8648080B2 (en) * 2009-07-09 2014-02-11 Raqualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
JP2014047304A (ja) * 2012-08-31 2014-03-17 Sanyo Chem Ind Ltd 樹脂粒子の製造方法
GB2508352B (en) * 2012-11-28 2017-08-16 Douwe Egberts Bv Treating soluble coffee
CA2896861A1 (en) * 2013-01-11 2014-07-17 Novartis Ag Meglumine salt forms of 2-((1r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors
PE20171259A1 (es) * 2014-12-19 2017-08-28 Glaxosmithkline Ip Dev Ltd Compuestos

Also Published As

Publication number Publication date
US20180009791A1 (en) 2018-01-11
GEP20196974B (en) 2019-06-10
PH12016000029B1 (en) 2017-07-24
HRP20201275T1 (hr) 2020-11-13
DK3248967T3 (da) 2020-09-07
RS60758B1 (sr) 2020-10-30
TW201627305A (zh) 2016-08-01
WO2016117814A2 (ko) 2016-07-28
IL253186A (en) 2018-04-30
EP3248967A2 (en) 2017-11-29
ES2816646T3 (es) 2021-04-05
CN107207478B (zh) 2020-09-01
PH12016000029A1 (en) 2017-07-24
MY186830A (en) 2021-08-24
EA030919B1 (ru) 2018-10-31
AR103444A1 (es) 2017-05-10
BR102016001167B1 (pt) 2023-03-07
JP6535748B2 (ja) 2019-06-26
WO2016117814A3 (ko) 2016-10-06
JP2018502140A (ja) 2018-01-25
KR101684053B1 (ko) 2016-12-08
CY1123423T1 (el) 2021-12-31
SI3248967T1 (sl) 2020-11-30
CN111187259A (zh) 2020-05-22
MX359916B (es) 2018-10-15
UY36521A (es) 2016-08-31
KR20160089928A (ko) 2016-07-29
SMT202000688T1 (it) 2021-01-05
US9908870B2 (en) 2018-03-06
LT3248967T (lt) 2020-10-12
ECSP17035416A (es) 2017-11-30
BR102016001167A2 (pt) 2018-03-20
JO3592B1 (ar) 2020-07-05
HUE050979T2 (hu) 2021-01-28
PH12019000462A1 (en) 2020-10-12
CN107207478A (zh) 2017-09-26
CL2017001377A1 (es) 2017-12-15
EA201791151A1 (ru) 2017-12-29
IL253186B (en) 2020-11-30
PT3248967T (pt) 2020-09-11
GEAP201914554A (en) 2019-01-25
EP3248967A4 (en) 2018-10-03
CN111187259B (zh) 2023-10-13
PL3248967T3 (pl) 2020-12-28
EP3248967B1 (en) 2020-06-24
CO2017005396A2 (es) 2017-07-11
SA517381904B1 (ar) 2020-12-07
JP2019104760A (ja) 2019-06-27
TWI589575B (zh) 2017-07-01
SG10201509488YA (en) 2016-08-30

Similar Documents

Publication Publication Date Title
UY36521A (es) Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
CO2017011754A2 (es) Amidas heterocíclicas como inhibidores de quinasa
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
MX2016010675A (es) Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
MX384426B (es) Proceso para preparar derivados de fenil sulfamoilpirrolamidas
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CL2019002321A1 (es) Procesos para preparar ag-10, sus intermediarios, y sales de los mismos.
BR112018002461A2 (pt) compostos para dispositivos opticamente ativos
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
BR112019014963A8 (pt) Compostos-bis para dispositivos opticamente ativos
AR103350A1 (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
UY35536A (es) ?derivados de sulfonamida?.
MX378942B (es) Cocristal y método para producir el mismo.
MX2018000829A (es) Resinas quelantes que contienen grupos de acido iminoacetico dopadas con aluminio.
PY1601448A (es) Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende

Legal Events

Date Code Title Description
FG Grant or registration